Hyperion DeFi, Inc.
HYPD Healthcare Biotechnology
Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,333.3%, EPS grew 140.4%, free cash flow grew 86.8% and total debt rose 12.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HYPD
Hyperion DeFi, Inc. (HYPD) Piotroski F-score
Hyperion DeFi, Inc.'s Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (169.57%) | (307.07%) | Fail | 0 |
| Positive operating cash flow | (14.77m) | (30.12m) | Fail | 0 |
| Rising return on assets | (169.57%) | (307.07%) | Pass | 1 |
| Cash flow above net income | 32.23m | 19.70m | Pass | 1 |
| Falling long-term leverage | 0.28 | 0.00 | Fail | 0 |
| Rising current ratio | 2.68 | 0.17 | Pass | 1 |
| No new shares issued | 5,000,300 | 833,000 | Fail | 0 |
| Rising gross margin | 62.72% | (6,753.75%) | Pass | 1 |
| Rising asset turnover | 0.03 | 0.00 | Pass | 1 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ELTX Elicio Therapeutics, Inc. compare | 6 |
| HYPD Hyperion DeFi, Inc. | 5 |
| ACET Adicet Bio, Inc. compare | 4 |
| IBIO iBio, Inc. compare | 4 |
| CRBU Caribou Biosciences, Inc. compare | 3 |
| HOWL Werewolf Therapeutics, Inc. compare | 3 |
| KLRS Kalaris Therapeutics Inc. compare | — |
| LONA LeonaBio, Inc. compare | — |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover